Healthcare

SB 191 establishes a state-run pilot program for psychedelic-assisted therapy using MDMA and psilocybin, effective July 1, 2026. It directly affects qualified patients in Connecticut who are 18+ and meet specific criteria (veterans, retired first responders, or healthcare workers), providing them access to therapy administered by a state-selected medical school. The program requires federal FDA approval under 21 CFR 312 for research purposes and will terminate once MDMA/psilocybin receive DEA approval for medical use. The bill repeals an existing statute and creates a structured framework for this therapeutic pilot program.

HB 5374 requires individual health insurance policies in Connecticut that cover chemotherapy to also provide coverage for scalp cooling systems used to prevent hair loss during treatment. This applies to policies delivered, renewed, or continued on or after January 1, 2027, and mandates coverage "at least equivalent to such coverage provided under Medicare." The bill specifically targets policies covering certain chemotherapy-related treatments, directly affecting patients receiving chemotherapy who may use scalp cooling systems. It does not apply to group plans or other insurance types, focusing solely on individual health insurance policies meeting the specified coverage criteria.